| Literature DB >> 26897420 |
Abstract
In this article, the processing of investigational and new drug applications is described and the standard and expedited review processes are examined. The efforts of the US Food and Drug Administration to ensure greater agency transparency and fiscal responsibility and intensify oversight during the drug development and approval process are reviewed. Often attributed to a decrease in the number of uninsured adults, both the increase in prescription drug sales and the high costs associated with bringing a new drug to market highlight the necessity for a streamlined and cost-effective process to deliver these drugs safely and effectively.Keywords: Drug approval; Drug review; Expedited reviews; Food and Drug Administration
Mesh:
Substances:
Year: 2016 PMID: 26897420 DOI: 10.1016/j.cnur.2015.10.007
Source DB: PubMed Journal: Nurs Clin North Am ISSN: 0029-6465 Impact factor: 1.208